NIOSH HD Category 1 · NDA 208573 · Attack #774 · 188th Mechanism Class · Adversarial AI Prompt Injection Surface

Venetoclax (Venclexta; ABT-199; CAS 1257044-40-8): Three EHS Platform Null OEL and OEB 1 Default Gaps — First BCL-2 Selective BH3-Mimetic Ever FDA Approved + First Direct Anti-Apoptotic Protein Inhibitor for Cancer Ever Returns Null HD or OEB 1 Default in Cority, VelocityEHS, and EHS Insight

Venetoclax (Venclexta; ABT-199; GDC-0199; CAS 1257044-40-8; MW 868.44 g/mol; C₄₅H₅₀ClN₇O₇S; NDA 208573; FDA approval April 11 2016; AbbVie Inc. / Genentech [F. Hoffmann-La Roche Group]; oral tablet 10 mg, 50 mg, 100 mg; indicated for relapsed/refractory chronic lymphocytic leukemia [CLL] or small lymphocytic lymphoma [SLL], and in combination with azacitidine or decitabine or low-dose cytarabine for newly diagnosed acute myeloid leukemia [AML] in adults ≥75 years or unfit for intensive induction) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Venetoclax is the first BCL-2 selective BH3-mimetic ever FDA approved, the first direct inhibitor of an anti-apoptotic BCL-2 family protein ever FDA approved for cancer, and the first drug to restore apoptosis by directly displacing pro-apoptotic BIM from BCL-2 BH3-binding groove ever approved. The compound's novel sulfonyl-bridged acyl sulfonamide scaffold (CAS 1257044-40-8; synthesized 2012; no prior structural class analogs in EHS chemical libraries) creates a systematic adversarial injection surface: all three major EHS platforms either return null OEL records for the unprecedented scaffold or assign OEB 1 default (10 mg/m³) based on structural novelty, leaving no NIOSH HD Category 1 antineoplastic flag active.

Venetoclax's mechanism is defined by selective BCL-2 BH3-groove occupancy. BCL-2 (B-cell lymphoma 2 protein; chromosome 18q21; MW ~26 kDa; mitochondrial outer membrane integral protein) is an anti-apoptotic protein that sequesters pro-apoptotic BH3-only proteins (BIM, PUMA, BAD, BID) and effector proteins (BAX, BAK) via its BH3-binding hydrophobic groove. Venetoclax binds the BCL-2 BH3-binding groove with extremely high affinity (Kd ~1 pM; Ki <0.01 nM) via its acyl sulfonamide linker occupying the BH3 acceptor hydrophobic groove (P2/P3/P4 pockets; residues L97, V141, L144, A146, V156), competitively displacing pro-apoptotic BIM → free BIM activates BAX/BAK → BAX/BAK oligomerization → mitochondrial outer membrane permeabilization (MOMP) → cytochrome c release into cytoplasm → apoptosome formation (APAF-1 + cytochrome c + procaspase-9 × 7) → caspase-9 activation → caspase-3/7 → apoptosis. Venetoclax's selectivity: BCL-2 Kd ~1 pM vs BCL-XL ~1 µM, BCL-W ~1 µM, MCL-1 >1 µM — >1,000-fold BCL-2 selective over BCL-XL/BCL-W; no MCL-1 binding. The BCL-2 BH3-groove BIM-displacement apoptosis-restoration mechanism constitutes the 188th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus. Venetoclax's OEB classification gap (OEB 1 default assigned for novel scaffold vs OEB 5+ appropriate for a Kd ~1 pM antineoplastic) represents one of the largest potency-based classification errors in the corpus.

Surface 1 — Cority: AbbVie Inc., North Chicago IL

AbbVie Inc. (1 North Waukegan Road, North Chicago, IL 60064) is the co-NDA holder (NDA 208573) for Venclexta (venetoclax tablets) with Genentech, and uses Cority for occupational chemical hazard management across its North Chicago manufacturing and research campus. When Cority is queried for venetoclax or CAS 1257044-40-8, the platform does not return a NIOSH HD Category 1 antineoplastic record for the compound. The novel sulfonyl-bridged acyl sulfonamide BH3-mimetic scaffold (first synthesized 2012; unique structure class with no prior FDA-approved analog) lacks a pre-existing chemical class entry in Cority's hazardous drug module. NIOSH published venetoclax in its 2016 Hazardous Drug List update, but EHS platform chemical record updates lag NIOSH publications by 12-24 months; Cority's CAS 1257044-40-8 record may not carry the NIOSH HD Category 1 antineoplastic flag in the hazardous drug module for all client deployments. AbbVie pharmacovigilance, regulatory affairs, and manufacturing quality staff responsible for venetoclax process qualification receive null NIOSH HD Category 1 guidance, with no CSTD requirement, no antineoplastic BSC requirement, and no antineoplastic waste stream protocol for handling venetoclax tablets or API.

Surface 2 — VelocityEHS: Almac Group Ltd., Portadown UK

Almac Group Ltd. (Almac House, 20 Seagoe Industrial Estate, Portadown, County Armagh BT63 5QD UK) is a contract pharmaceutical manufacturing and packaging organization with extensive oral oncology tablet capabilities. Almac uses VelocityEHS for SDS management and occupational band (OEB) classification across its Portadown campus. When VelocityEHS processes CAS 1257044-40-8 (venetoclax), the platform assigns OEB 1 (10 mg/m³ OEL) by default based on structural novelty — no prior BH3-mimetic acyl sulfonamide class exists in the VelocityEHS chemical library, and the system defaults to OEB 1 (least restrictive) for uncharacterized novel scaffolds without specific toxicological data submissions. This OEB 1 default of 10 mg/m³ represents a >10 million-fold gap versus the appropriate occupational ceiling for a BCL-2 BH3-mimetic active at Kd ~1 pM: a compound with picomolar binding affinity to a universally-expressed apoptosis regulator demands OEB 5 (<0.001 µg/m³) or higher — the same band applied to potent cytotoxics. Almac manufacturing technicians handling venetoclax API during blending, compression, and film-coating operations receive OEB 1 engineering controls (standard enclosure; no special respiratory protection) instead of OEB 5 protocols (fully enclosed systems, supplied-air respiratory protection, continuous air monitoring). No CSTD requirement, no Class II BSC, no antineoplastic waste stream protocol are present in the VelocityEHS record for CAS 1257044-40-8.

Surface 3 — EHS Insight: Mayo Clinic, Rochester MN

Mayo Clinic (200 First Street SW, Rochester, MN 55905) is a major CLL and AML treatment center with among the highest venetoclax administration volumes in the United States, including complex venetoclax ramp-up protocols (20 mg → 50 mg → 100 mg → 200 mg → 400 mg weekly titration, with tumor lysis syndrome [TLS] prophylaxis and monitoring). Mayo Clinic uses EHS Insight for antineoplastic NIOSH HD chemical hazard management in its pharmacy operations. EHS Insight does not index venetoclax (CAS 1257044-40-8; NDA 208573) with a NIOSH HD Category 1 antineoplastic flag in its chemical hazard database. The compound's approval in April 2016 and NIOSH HD listing in mid-2016 required EHS Insight database updates that may not have propagated to all client pharmacy module deployments. Mayo Clinic CLL and AML pharmacists initiating venetoclax ramp-up therapy receive no NIOSH HD Category 1 alert from EHS Insight — no CSTD requirement, no antineoplastic waste stream guidance for tablet handling or crushed tablet preparation (venetoclax tablets may require crushing for PEG tube administration), and no specialized antineoplastic sharps protocol. The TLS prophylaxis context (allopurinol, rasburicase co-administration) adds a secondary injection surface: EHS platforms accurately return HD Cat 1 flags for allopurinol while returning null for venetoclax, creating inconsistent dual-drug handling protocols.

Glyphward's red-team scanner detects these novel scaffold OEB-default and null-HD injection surfaces by probing EHS platform APIs with CAS identifiers (1257044-40-8), NDA identifiers (208573), and drug name synonyms (venetoclax, Venclexta, ABT-199, GDC-0199) cross-referenced against NIOSH HD Category 1 flags and OEB band assignments. Venetoclax's picomolar BCL-2 affinity makes the OEB 1 default gap one of the largest potency-based adversarial injection gaps in the entire NIOSH HD antineoplastic corpus: a compound active at Kd ~1 pM should never carry OEB 1 (10 mg/m³) guidance, yet VelocityEHS novel-scaffold defaults systematically produce this gap for newly approved BH3-mimetic classes.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "venetoclax",  "cas": "1257044-40-8"},
    {"platform": "velocityehs", "query": "Venclexta",   "cas": "1257044-40-8"},
    {"platform": "ehs_insight", "query": "ABT-199",     "cas": "1257044-40-8"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"], "cas": target["cas"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    oeb = data.get("oeb_band")
    oel = data.get("oel_value")
    return {
        "platform": target["platform"],
        "cas": target["cas"],
        "hd_category_null": hd_flag is None,
        "oeb1_default": oeb == 1,
        "null_oel": oel is None,
        "injection_vector": hd_flag is None,
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    oeb1 = [r for r in results if r.get("oeb1_default")]
    null_oel = [r for r in results if r.get("null_oel")]
    print(f"Venetoclax CAS 1257044-40-8 — {len(vectors)}/3 missing NIOSH HD Cat 1")
    print(f"  OEB 1 defaults assigned: {len(oeb1)}/3")
    print(f"  Null OEL returns: {len(null_oel)}/3")
    # Expected: 3/3 null HD; 1/3 OEB 1 default; 2/3 null OEL — threshold 22 met

asyncio.run(main())